A noninvasive accelerated quantitative MR technique to distinguish drug resistance in prolactinomas: Early results
Management of dopamine agonist (DA) resistance in prolactinoma (PRLoma) remains challenging due to the lack of detecting approach and reliable imaging marker. In this cross-sectional study, PRLoma patients were recruited prospectively from a single-center outpatient clinic from May 2024 to September...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KeAi Communications Co., Ltd.
2025-06-01
|
| Series: | Biomedical Technology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2949723X25000182 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849471639479123968 |
|---|---|
| author | Rong Lu Tingfang Hwang Kaibo Tang Qing Li Caixia Fu Ying-Hua Chu Shangxuan Shi Tobias Kober Tom Hibert Bin Lu Yiming Li Yao Lu Weijun Tang Lijin Ji |
| author_facet | Rong Lu Tingfang Hwang Kaibo Tang Qing Li Caixia Fu Ying-Hua Chu Shangxuan Shi Tobias Kober Tom Hibert Bin Lu Yiming Li Yao Lu Weijun Tang Lijin Ji |
| author_sort | Rong Lu |
| collection | DOAJ |
| description | Management of dopamine agonist (DA) resistance in prolactinoma (PRLoma) remains challenging due to the lack of detecting approach and reliable imaging marker. In this cross-sectional study, PRLoma patients were recruited prospectively from a single-center outpatient clinic from May 2024 to September 2024. A noninvasive accelerated quantitative MR technique (GRAPPATINI, GeneRalized Autocalibrating Partially Parallel Acquisitions acceleraTed T2 mappINg) was applied to investigate the correlation between quantitative T2 values and DA resistance. The T2 values of tumors with multiple echo times (TEs) and signal intensity (SI) ratios were analyzed. A total of 30 participants were included, of which 20 were DA-sensitive and 10 were DA-resistant. The T2 values were significantly lower in DA-resistant PRLoma than those in DA-sensitive PRLoma (76.85 ± 29.84 ms vs 135.88 ± 69.86 ms, P = 0.0048), whereas the T2 SI ratio revealed no significant difference. The area under the curve (AUC) of T2 values and T2 SI ratio for distinguishing DA sensitivity were 0.850 and 0.668, respectively. The ratio distributions at different TEs (TE10 ms, TE38 ms, TE42 ms, TE55 ms, and TE90 ms) were significantly different at TE38 ms (P = 0.026) between two groups. The AUC of T2 values and TEs for DA sensitivity in PRLoma were 0.850 (T2map), 0.680 (TE10 ms), 0.730 (TE38 ms), 0.690 (TE42 ms), 0.520 (TE55 ms), and 0.670 (TE90 ms), respectively (P = 0.0107). These findings highlight the translational potential of T2 values as a promising imaging biomarker for evaluating DA resistance in PRLoma. |
| format | Article |
| id | doaj-art-a301b366b5d94541a80e8790ca06b4fa |
| institution | Kabale University |
| issn | 2949-723X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | KeAi Communications Co., Ltd. |
| record_format | Article |
| series | Biomedical Technology |
| spelling | doaj-art-a301b366b5d94541a80e8790ca06b4fa2025-08-20T03:24:45ZengKeAi Communications Co., Ltd.Biomedical Technology2949-723X2025-06-011010008610.1016/j.bmt.2025.100086A noninvasive accelerated quantitative MR technique to distinguish drug resistance in prolactinomas: Early resultsRong Lu0Tingfang Hwang1Kaibo Tang2Qing Li3Caixia Fu4Ying-Hua Chu5Shangxuan Shi6Tobias Kober7Tom Hibert8Bin Lu9Yiming Li10Yao Lu11Weijun Tang12Lijin Ji13Department of Radiology, Huashan Hospital, Fudan University, Shanghai, ChinaDepartment of Radiology, Huashan Hospital, Fudan University, Shanghai, ChinaDepartment of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USAMR Research Collaboration, Siemens Healthineers Ltd., Shanghai, ChinaApplication Developments, Siemens Shenzhen Magnetic Resonance Ltd, Shanghai, Shenzhen, 518057, ChinaMR Research Collaboration, Siemens Healthineers Ltd., Shanghai, ChinaShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, ChinaLTS5, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland; Department of Radiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; Advanced Clinical Imaging Technology, Siemens Healthineers International AG, Lausanne, SwitzerlandLTS5, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland; Department of Radiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; Advanced Clinical Imaging Technology, Siemens Healthineers International AG, Lausanne, SwitzerlandDepartment of Endocrinology, Huashan Hospital, Fudan University, Shanghai, China; Department of Endocrinology, Huadong Hospital, Fudan University, Shanghai, ChinaDepartment of Endocrinology, Huashan Hospital, Fudan University, Shanghai, China; Huashan Rare Disease Center, Huashan Hospital, Fudan University, Shanghai, ChinaDepartment of Joint and Orthopedics, Orthopedic Center, Clinical Research Center, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China; Corresponding author.Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China; Corresponding author.Department of Endocrinology, Huashan Hospital, Fudan University, Shanghai, China; Huashan Rare Disease Center, Huashan Hospital, Fudan University, Shanghai, China; Corresponding author. Department of Endocrinology, Huashan Hospital, Fudan University, Shanghai, China.Management of dopamine agonist (DA) resistance in prolactinoma (PRLoma) remains challenging due to the lack of detecting approach and reliable imaging marker. In this cross-sectional study, PRLoma patients were recruited prospectively from a single-center outpatient clinic from May 2024 to September 2024. A noninvasive accelerated quantitative MR technique (GRAPPATINI, GeneRalized Autocalibrating Partially Parallel Acquisitions acceleraTed T2 mappINg) was applied to investigate the correlation between quantitative T2 values and DA resistance. The T2 values of tumors with multiple echo times (TEs) and signal intensity (SI) ratios were analyzed. A total of 30 participants were included, of which 20 were DA-sensitive and 10 were DA-resistant. The T2 values were significantly lower in DA-resistant PRLoma than those in DA-sensitive PRLoma (76.85 ± 29.84 ms vs 135.88 ± 69.86 ms, P = 0.0048), whereas the T2 SI ratio revealed no significant difference. The area under the curve (AUC) of T2 values and T2 SI ratio for distinguishing DA sensitivity were 0.850 and 0.668, respectively. The ratio distributions at different TEs (TE10 ms, TE38 ms, TE42 ms, TE55 ms, and TE90 ms) were significantly different at TE38 ms (P = 0.026) between two groups. The AUC of T2 values and TEs for DA sensitivity in PRLoma were 0.850 (T2map), 0.680 (TE10 ms), 0.730 (TE38 ms), 0.690 (TE42 ms), 0.520 (TE55 ms), and 0.670 (TE90 ms), respectively (P = 0.0107). These findings highlight the translational potential of T2 values as a promising imaging biomarker for evaluating DA resistance in PRLoma.http://www.sciencedirect.com/science/article/pii/S2949723X25000182Accelerated quantitative T2 mappingDA resistanceGRAPPATINIProlactinoma |
| spellingShingle | Rong Lu Tingfang Hwang Kaibo Tang Qing Li Caixia Fu Ying-Hua Chu Shangxuan Shi Tobias Kober Tom Hibert Bin Lu Yiming Li Yao Lu Weijun Tang Lijin Ji A noninvasive accelerated quantitative MR technique to distinguish drug resistance in prolactinomas: Early results Biomedical Technology Accelerated quantitative T2 mapping DA resistance GRAPPATINI Prolactinoma |
| title | A noninvasive accelerated quantitative MR technique to distinguish drug resistance in prolactinomas: Early results |
| title_full | A noninvasive accelerated quantitative MR technique to distinguish drug resistance in prolactinomas: Early results |
| title_fullStr | A noninvasive accelerated quantitative MR technique to distinguish drug resistance in prolactinomas: Early results |
| title_full_unstemmed | A noninvasive accelerated quantitative MR technique to distinguish drug resistance in prolactinomas: Early results |
| title_short | A noninvasive accelerated quantitative MR technique to distinguish drug resistance in prolactinomas: Early results |
| title_sort | noninvasive accelerated quantitative mr technique to distinguish drug resistance in prolactinomas early results |
| topic | Accelerated quantitative T2 mapping DA resistance GRAPPATINI Prolactinoma |
| url | http://www.sciencedirect.com/science/article/pii/S2949723X25000182 |
| work_keys_str_mv | AT ronglu anoninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT tingfanghwang anoninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT kaibotang anoninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT qingli anoninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT caixiafu anoninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT yinghuachu anoninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT shangxuanshi anoninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT tobiaskober anoninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT tomhibert anoninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT binlu anoninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT yimingli anoninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT yaolu anoninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT weijuntang anoninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT lijinji anoninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT ronglu noninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT tingfanghwang noninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT kaibotang noninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT qingli noninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT caixiafu noninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT yinghuachu noninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT shangxuanshi noninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT tobiaskober noninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT tomhibert noninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT binlu noninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT yimingli noninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT yaolu noninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT weijuntang noninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults AT lijinji noninvasiveacceleratedquantitativemrtechniquetodistinguishdrugresistanceinprolactinomasearlyresults |